Item 8.01. Other Events.
OnNovember 30, 2021 ,BeiGene, Ltd. (the "Company" or "BeiGene") issued a press release announcing the pricing of its initial public offering on the Science and Technology Innovation Board (the "STAR Market") of theShanghai Stock Exchange inChina . A copy of this press release is attached hereto as Exhibit 99.1, and is incorporated herein by reference. OnDecember 2, 2021 , the Company issued a press release announcing that theChina National Medical Products Administration (NMPA) has approved SYLVANT® (siltuximab for injection) for the treatment of adult patients with multicentric Castleman disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpes virus-8 (HHV-8) negative, also known as idiopathic MCD (iMCD). A copy of this press release is attached hereto as Exhibit 99.2, and is incorporated herein by reference. OnDecember 2, 2021 , the Company issued a press release announcing that three of its medicines have been added to the most recent National Reimbursement Drug List ("NRDL") inChina by theNational Healthcare Security Administration .BeiGene -discovered medicines in the updated NRDL include: anti-PD-1 antibody tislelizumab in three new indications, including in lung and liver cancers; BTK inhibitor BRUKINSA® (zanubrutinib) in one new indication; and the initial listing for PARP inhibitor pamiparib. The changes to the NRDL will be effective onJanuary 1, 2022 . A copy of this press release is attached hereto as Exhibit 99.3, and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. Exhibit No. Description 99.1 Press Release titled "BeiGene Announces Pricing of itsRMB22.2 billion (US$3.5 billion ) Initial Public Offering on the
STAR Market of the
Stock Exchange inChina ", issued byBeiGene, Ltd.
on
99.2 Press Release titled "BeiGene and EUSA Pharma
Announce NMPA Approval of
SYLVANT® (Siltuximab for Injection) inChina for Idiopathic Multicentric Castleman Disease", issued byBeiGene, Ltd. onDecember 2, 2021 . 99.3 Press Release titled "BeiGene Announces Inclusion in the China National Reimbursement Drug List (NRDL) of Tislelizumab in Three New Indications, BRUKINSA® (zanubrutinib) in One New Indication,
and the First Listing for
Pamiparib", issued byBeiGene, Ltd. on December
2, 2021.
104 The cover page from this Current Report on Form
8-K, formatted in Inline
XBRL
--------------------------------------------------------------------------------
© Edgar Online, source